Bristol Myers Squibb: the value of immuno-oncology in serving patients

Bristol Myers Squibb (BMS), a leading biopharmaceutical company, held a press conference in Cyprus on June 9, 2026, during which distinguished medical oncologists highlighted the key factors for improving cancer patient care. Particular emphasis was placed on early diagnosis, the multidisciplinary approach and modern treatment options, with immuno-oncology taking centre stage as a transformative force […]